Non-small cell lung cancer with BRAF mutation treated with neoadjuvant targeted therapy followed by surgery: A case report
- VernacularTitle:BRAF突变非小细胞肺癌新辅助靶向治疗后手术一例
- Author:
Yingze NING
1
;
Chutong LIN
1
;
Xiang ZHU
2
;
Guangliang QIANG
1
Author Information
1. Department of Thoracic Surgery, Peking University Third Hospital, Beijing, 100191, P. R. China
2. Department of Pathology, Peking University Third Hospital, Beijing, 100191, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
BRAF mutation;
neoadjuvant therapy;
targeted therapy;
radical surgery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(07):1149-1152
- CountryChina
- Language:Chinese
-
Abstract:
This study reports a case of a 56-year-old female patient with BRAF-mutated non-small cell lung cancer (NSCLC) who successfully underwent radical surgery after neoadjuvant targeted therapy with the BRAF inhibitor dabrafenib combined with the MEK inhibitor trametinib. The chest drainage tube was removed 2 days postoperatively, and the patient was discharged smoothly. Postoperative pathology indicated invasive adenocarcinoma, moderately to highly differentiated, with 80% being lepidic type, and the maximum tumor diameter was 4 cm. No vascular tumor thrombus, vascular invasion, nerve invasion, spread through air spaces, pleural invasion, or lymph node metastasis were observed. The postoperative staging was ypT2aN0M0. The patient continued with adjuvant treatment with dabrafenib combined with trametinib postoperatively, and no signs of recurrence were found in the follow-up examination six months after surgery.
